Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports

Analysis of the brain specific biomarkers amyloid β(42) (Aβ(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Slats, Diane, Spies, Petra E., Sjögren, Magnus J.C., Verhey, Frans R.J., Verbeek, Marcel M., Olde Rikkert, Marcel G.M.
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: February 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914365/
https://www.ncbi.nlm.nih.gov/pubmed/20689628
http://dx.doi.org/10.1159/000286280
Descripción
Sumario:Analysis of the brain specific biomarkers amyloid β(42) (Aβ(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.

Ejemplares similares